Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST)
暂无分享,去创建一个
G. Demetri | P. Rutkowski | P. Hohenberger | P. Casali | H. Gelderblom | P. Reichardt | S. Bauer | J. Blay | C. Kappeler | I. Kuss | Y. Kang